A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine

Get answers to your Myelodysplastic Syndromes questions.
Brain lymphoma; Cerebral lymphoma; Primary lymphoma of the central nervous system; Lymphoma - brain
Primary lymphoma of the brain is cancer of the lymph cells that starts in the brain.
The cause of primary brain lymphoma is not known. It is more common in people ages 45 - 70.
Patients who have a weakened immune system are at greater risk for primary lymphoma of the brain. Common causes of a weakened immune system include:
Primary lymphoma of the brain is also linked to Epstein-Barr Virus (EBV), the virus that causes mononucleosis, especially in people with HIV infection.
The rate of primary brain lymphoma is rising. However, this cancer is still rare.
The following tests may be done to help diagnose a primary lymphoma of the brain:
The condition is usually first treated with corticosteroids to control swelling and improve symptoms. However, chemotherapy may increase survival by 3 - 4 years, or longer. The chemotherapy is usually high doses of methotrexate given through a vein (intravenously) or a spinal tap (intrathecally).
Treating patients with weakened immune systems is not as successful, but it is improving.
Radiation therapy was once the main treatment for primary lymphoma of the brain. Now it is usually only given to patients who do not respond to chemotherapy.
Many patients receive more than one treatment. This combination therapy includes drugs such as temozolomide, rituximab, cytarabine, and etoposide.
Recently, younger patients have been treated with high doses of chemotherapy. After the chemotherapy, they have an autologous stem cell transplant.
Without treatment, patients with primary brain lymphoma survive for less than 2 months. Patients who are treated with chemotherapy often survive 3 - 4 years or more.
About 40% of patients are alive at 5 years. In general, older patients have a worse outlook than younger patients.
Possible complications include:
National Comprehensive Cancer Network.
National Cancer Institute.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885